Rocket Pharmaceuticals (NASDAQ:RCKT) Given Buy Rating at Needham & Company LLC

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of […]

Related Keywords

United States ,America ,Gaurav Shah ,Jonathan David Schwartz ,Institutional Trading Of Rocket Pharmaceuticals ,Wells Fargo Company ,Morgan Stanley ,Analyst Recommendations For Rocket Pharmaceuticals ,Rocket Pharmaceuticals ,Rocket Pharmaceuticals Stock ,Rocket Pharmaceuticals Inc ,Nasdaq ,Nelson Van Denburg Campbell Wealth Management Group ,Life Insurance Co ,Needham Company ,Securities Exchange Commission ,News Ratings For Rocket Pharmaceuticals Daily ,Get Rating ,Exchange Commission ,Life Insurance ,Nelson Van Denburg ,Campbell Wealth Management Group ,Van Denburg ,Rocket Pharmaceuticals Daily ,Nasdaq Rckt ,Rckt ,Medical ,Reiterated Rating ,Needham Company Llc ,